- Home
- APGE
as 12-18-2024 10:31am EST
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.
| Founded: | 2022 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 3.0B | IPO Year: | 2023 |
| Target Price: | $75.40 | AVG Volume (30 days): | 588.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $22.20 - $72.29 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Apogee Therapeutics Inc. (APGE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| McKenna Mark C. | APGE | Director | Dec 12 '24 | Buy | $49.44 | 20,000 | $990,775.00 | 20,000 | |
| Dambkowski Carl | APGE | Chief Medical Officer | Dec 11 '24 | Sell | $49.31 | 4,540 | $221,362.70 | 258,528 | |
| Dambkowski Carl | APGE | Chief Medical Officer | Nov 6 '24 | Sell | $59.44 | 6,665 | $394,041.10 | 258,528 | |
| HENDERSON MICHAEL THOMAS | APGE | Chief Executive Officer | Nov 6 '24 | Sell | $59.56 | 15,000 | $888,320.00 | 1,340,487 | |
| Dambkowski Carl | APGE | Chief Medical Officer | Oct 2 '24 | Sell | $56.51 | 6,665 | $374,953.90 | 258,528 | |
| HENDERSON MICHAEL THOMAS | APGE | Chief Executive Officer | Oct 2 '24 | Sell | $56.41 | 40,000 | $2,249,307.04 | 1,340,487 |
Latest Apogee Therapeutics Inc. News
APGE Breaking Stock News: Dive into APGE Ticker-Specific Updates for Smart Investing
Argus Research
a day ago
Daily – Vickers Top Buyers & Sellers for 12/17/2024
GlobeNewswire
8 days ago
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions
TipRanks
15 days ago
Apogee Therapeutics Advances in I&I Disease Treatments
MT Newswires
16 days ago
Wedbush Adjusts Price Target on Apogee Therapeutics to $90 From $87, Maintains Outperform Rating
GlobeNewswire
16 days ago
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day
GlobeNewswire
19 days ago
Apogee Therapeutics Announces Agenda for Virtual R&D Day
MT Newswires
23 days ago
Canaccord Genuity Initiates Apogee Therapeutics at Buy With $89 Price Target
GlobeNewswire
a month ago
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024
Compare APGE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APGE Apogee Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.